Key regions: France, Europe, United Kingdom, Brazil, India
The demand for Oncology Drugs in Cambodia has been increasing over the years due to various factors that have contributed to the growth of the market.
Customer preferences: Cambodia has a growing elderly population, which has led to an increase in cancer cases. As a result, there has been a rise in demand for Oncology drugs in the country. Additionally, the government has been investing in healthcare infrastructure, which has increased access to healthcare services, including cancer treatment.
Trends in the market: The Oncology Drugs market in Cambodia is expected to grow at a steady pace due to the increasing incidence of cancer cases in the country. The market is dominated by multinational pharmaceutical companies that offer a wide range of Oncology drugs. However, there has been a rise in the number of local pharmaceutical companies that are manufacturing and distributing Oncology drugs in the country. This has led to increased competition in the market, which has resulted in lower prices of Oncology drugs.
Local special circumstances: Cambodia is a developing country with a relatively low GDP per capita. As a result, the cost of healthcare services, including cancer treatment, is a major concern for most Cambodians. The government has been working to address this issue by investing in healthcare infrastructure and providing subsidies for cancer treatment. Additionally, there is a lack of awareness about cancer prevention and treatment in the country, which has led to a delay in the diagnosis and treatment of cancer cases.
Underlying macroeconomic factors: The Cambodian economy has been growing steadily over the years, which has led to an increase in disposable income among the population. This has resulted in an increase in demand for healthcare services, including cancer treatment. The government has also been working to attract foreign investment in the country, which has led to the establishment of multinational pharmaceutical companies in the country. Additionally, the government has been investing in infrastructure development, including healthcare facilities, which has increased access to healthcare services in the country.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
